Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research note issued on Saturday.
Tonix Pharmaceuticals Price Performance
Shares of NASDAQ TNXP opened at $1.67 on Friday. The firm’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.91. Tonix Pharmaceuticals has a 12 month low of $1.65 and a 12 month high of $29.94. The stock has a market capitalization of $17.27 million, a price-to-earnings ratio of -0.09 and a beta of 2.17.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) last announced its quarterly earnings results on Monday, March 13th. The company reported ($3.50) earnings per share for the quarter, beating the consensus estimate of ($5.38) by $1.88. Analysts anticipate that Tonix Pharmaceuticals will post -9.56 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tonix Pharmaceuticals
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800.
- Get a free copy of the StockNews.com research report on Tonix Pharmaceuticals (TNXP)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.